MBX vs. HBP, SCYB, COM, NVH, IGX, MDNA, PDP, COV, SVA, and EMH
Should you be buying Microbix Biosystems stock or one of its competitors? The main competitors of Microbix Biosystems include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), Pediapharm (PDP), Covalon Technologies (COV), Sernova (SVA), and Emerald Health Therapeutics (EMH). These companies are all part of the "biotechnology" industry.
Microbix Biosystems vs. Its Competitors
Microbix Biosystems (TSE:MBX) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Microbix Biosystems has higher revenue and earnings than Helix BioPharma. Microbix Biosystems is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.
Microbix Biosystems has a net margin of 13.86% compared to Helix BioPharma's net margin of 0.00%. Helix BioPharma's return on equity of 1,803.57% beat Microbix Biosystems' return on equity.
0.2% of Microbix Biosystems shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Helix BioPharma had 4 more articles in the media than Microbix Biosystems. MarketBeat recorded 4 mentions for Helix BioPharma and 0 mentions for Microbix Biosystems. Helix BioPharma's average media sentiment score of 0.24 beat Microbix Biosystems' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.
Microbix Biosystems has a beta of 0.060098, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Helix BioPharma has a beta of -0.449843, suggesting that its stock price is 145% less volatile than the S&P 500.
Summary
Microbix Biosystems beats Helix BioPharma on 8 of the 12 factors compared between the two stocks.
Get Microbix Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Microbix Biosystems Competitors List
Related Companies and Tools
This page (TSE:MBX) was last updated on 9/13/2025 by MarketBeat.com Staff
